ATAZANAVIR

Course overview

ATAZANAVIR IS FDA APPROVED FOR THE TREATMENT OF HIV-1 INFECTION, IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR PATIENTS WHO ARE 3-MONTHS-OLD OR OLDER, WEIGHING 5 OR MORE KILOGRAMS. IT IS IN THE PROTEASE INHIBITOR CLASS OF HIV-1 MEDICATIONS. THIS ACTIVITY WILL HIGHLIGHT THE INDICATIONS, MECHANISM OF ACTION, ADMINISTRATION, ADVERSE EFFECTS, CONTRAINDICATIONS, AND MONITORING FOR ATAZANAVIR PERTINENT FOR MEMBERS OF THE HEALTHCARE TEAM IN THE MANAGEMENT OF PATIENTS WITH HIV/AIDS.